MRK241220P110000
- 10.85
- +0.50+4.83%
メルクのニュース一覧
大摩：予翰森制药“增持”评级 目标价24港元
Merck (MRK) Stock Moves -1.72%: What You Should Know
Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases
Sector Update: Health Care Stocks Advance in Afternoon Trading
Sector Update: Health Care
Merck Makes Another Play for Lucrative Obesity-Drug Market -- WSJ
10 Health Care Stocks With Whale Alerts In Today's Session
Dow's Drop: How Blue-chips Have Fared During Index's Peak Turned Worst-run in Decades
翰森製藥(03692.HK)向默沙東授出HS-10535獨家許可 獲首付款1.12億美元
Merck-Hansoh Deal for Oral GLP-1 Hurts Obesity Drug Developers
What's Going On With Merck Shares Wednesday?
Merck's BLA for RSV Antibody Clesrovimab Gets FDA Acceptance
价值20亿美元！翰森制药授予默沙东口服减肥药全球独家许可权
Merck to End Development of Two Cancer Candidates: Time to Sell?
默克(MRK.US)20億美元向中國藥廠購買減肥藥全球獨家許可
默沙东(MRK.US)预防性长效单克隆抗体clesrovimab上市申请获FDA接受
Merck to Develop Weight Loss Pill From Chinese Drugmaker in up to $2 Billion Licensing Deal
Merck, Hansoh Pharma Enter Exclusive Global License Agreement For HS-10535, An Investigational Preclinical Oral Small Molecule GLP-1 Receptor Agonist; Hansoh To Receive An Upfront Payment Of $112M And Up To $1.9B In Milestones
Merck in Pact for Chinese Obesity Drug in Nearly $2 Billion Deal
翰森制药(03692.HK)与默沙东订立全球独家许可协议